*Health Canada License No 84512 for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI). The CO2RE laser platform is not FDA-cleared for the treatment of GSM or SUI.
Research suggests that up to 50 percent of menopausal women experience genitourinary syndrome of menopause (GSM). While many women endure the effects that GSM has on life, left untreated, the symptoms associated with GSM can adversely affect the patient's confidence and overall quality of life.
In this podcast, board-certified ObGyn, Falguni Patel, MD, FACOG, will discuss menopause and the different treatment options available for GSM, including the use of CO2. Further, Dr. Patel tells us about how she uses Candela’s CO2RE® laser for the treatment of GSM in her practice.